retatrutide weight loss trial VisualAbstract: reduces body by 17.5% in patients with obesity Effects of once-weekly subcutaneous retatrutide

Eur Respir Rev

GLP-1R agonists were initially developed for the treatment of type 2 diabetes

If left untreated, fatty liver disease can move through distinct stages of severity: The risk of progression is significantly higher in people with obesity, diabetes, and long-standing metabolic disease

doi: 10.1007/s13668-018-0248-8 21 ChangP

Safe, medically supervised weight management Steady and sustainable progress without extreme dieting Improved energy, focus, and overall well-being Personalized dosing and regular progress monitoring Confidence knowing youre supported by a trusted medical team Our goal is to help you build healthy habits that last long after treatment, with guidance you can count on every step of the way